Inflammatory markers at start and end of acute Charcot Arthropathy: Use TNF alpha and IL6?

Compelling work from our friends Nina Petrova, Mike Edmonds, et al at King's College, London. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy N. L. Petrova1,*, T. K. Dew2, R. L. Musto2, R. A. Sherwood2, M. Bates1, C. F. Moniz2 andM. E. Edmonds1 Aims To assess markers of inflammation and bone turnover at presentation and at resolution of Charcot osteoarthropathy. Methods We measured serum inflammatory and bone turnover markers in a cross-sectional study of 35 people with Charcot osteoarthropathy, together with 34 people with diabetes and 12 people without diabetes. In addition, a prospective study of the subjects with Charcot osteoarthropathy was conducted until clinical resolution. Results At presentation, high-sensitivity C-reactive protein (P=0.007), tumour necrosis factor-α (P=0.010) and interleukin-6 (P=0.002), but not interleukin-1β, (P=0.254) were significantly higher in people with Charcot osteoarthropathy than in people with and without diabetes. Serum C-terminal telopeptide (P=0.004), bone alkaline phosphatase (P=0.006) and osteoprotegerin (P